Metformin in pregnancy and childhood neurodevelopmental outcomes: a systematic review and meta-analysis

Hannah G Gordon; Jessica A Atkinson; Stephen Tong; Parinaz Mehdipour; Catherine Cluver; Susan P Walker; Anthea C Lindquist; Roxanne M Hastie

doi:10.1016/j.ajog.2024.02.316

Metformin in pregnancy and childhood neurodevelopmental outcomes: a systematic review and meta-analysis

Am J Obstet Gynecol. 2024 Mar 7:S0002-9378(24)00430-7. doi: 10.1016/j.ajog.2024.02.316. Online ahead of print.

Authors

Hannah G Gordon¹, Jessica A Atkinson², Stephen Tong², Parinaz Mehdipour², Catherine Cluver³, Susan P Walker², Anthea C Lindquist², Roxanne M Hastie²

Affiliations

¹ Department of Obstetrics and Gynaecology, University of Melbourne, Victoria, Australia; Mercy Perinatal, Mercy Hospital for Women, Heidelberg, Victoria, Australia. Electronic address: hannah.gordon@unimelb.edu.au.
² Department of Obstetrics and Gynaecology, University of Melbourne, Victoria, Australia; Mercy Perinatal, Mercy Hospital for Women, Heidelberg, Victoria, Australia.
³ Department of Obstetrics and Gynaecology, University of Melbourne, Victoria, Australia; Mercy Perinatal, Mercy Hospital for Women, Heidelberg, Victoria, Australia; Department of Obstetrics and Gynaecology, Stellenbosch University, Tygerberg Hospital, South Africa.

PMID: 38460832
DOI: 10.1016/j.ajog.2024.02.316

Abstract

Objective: This study aimed to examine the impact of maternal metformin use during pregnancy on offspring neurodevelopmental outcomes.

Data sources: MEDLINE, Embase, and Web of Science (Core Collection) were searched from inception until July 1, 2023.

Study eligibility criteria: Studies of women who received treatment with metformin at any stage of pregnancy for any indication with neurodevelopmental data available for their offspring were included. Studies without a control group were excluded. Randomized controlled trials, case-control, cohort, and cross-sectional studies were included in the review.

Methods: Studies were screened for inclusion and data were extracted independently by 2 reviewers. Risk of bias was assessed using a modified version of the Newcastle-Ottawa Scale for nonrandomized studies, and the Risk of Bias 2 tool for randomized trials.

Results: A total of 7 studies met the inclusion criteria, including a combined cohort of 14,042 children with 7641 children who were exposed and followed for up to 14 years of age. Metformin use during pregnancy was not associated with neurodevelopmental delay in infancy (relative risk, 1.09; 95% confidence interval, 0.54-2.17; 3 studies; 9668 children) or at ages 3 to 5 years (relative risk, 0.90; 95% confidence interval, 0.56-1.45; 2 studies; 6118 children). When compared with unexposed peers, metformin use during pregnancy was not associated with altered motor scores (mean difference, 0.30; 95% confidence interval, -1.15 to 1.74; 3 studies; 714 children) or cognitive scores (mean difference, -0.45; 95% confidence interval, -1.45 to 0.55; 4 studies; 734 children). Studies that were included were of high quality and deemed to be at low risk of bias.

Conclusion: In utero exposure to metformin does not seem to be associated with adverse neurodevelopmental outcomes in children up to the age of 14 years. These findings provide reassurance to clinicians and pregnant women considering metformin use during pregnancy.

Keywords: child development; gestational diabetes mellitus; metformin; offspring.

Publication types

Review